Parimal Nathwani MSc, MBA, President and CEO
Mr. Nathwani is biotechnology executive with over 15 years of experience working in the area of new venture creation, financing, business development, licensing and corporate strategy. Prior to his current roles, Parimal was a healthcare analyst with a boutique investment bank, where he conducted due diligence on publicly-traded biotechnology companies in Canada and the U.S. for an institutional investor client base and advised companies on financing strategies. He has also held the position of technology transfer manager in the life sciences at one of Canada’s leading technology transfer offices and business development executive within a venture backed biotechnology company. Parimal received his Masters of Science degree from University of British Columbia and his MBA from Simon Fraser University. Parimal also is an active participant within the biotechnology community - he is the Executive Chairman of ScaRX Therapeutics and a board observer for Encycle Therapeutics and DLVR Therapeutics..
Dr. Paul Van Slyke PhD, Chief Scientific Officer
Dr. Van Slyke leads all scientific efforts for the company including overall scientific strategy, advising on preclinical study designs, overseeing contract sites, troubleshooting with research and technical staff and overall scientific operations at Vasomune. With over a decade of research experience related to the Tie2 pathway and co-inventor on the Vasculotide technology, Paul has dedicated his research career to the translation of this pathway into clinical practice. Paul received his PhD in the lab of Dr. Dan Dumont at Sunnybrook Research Institute, University of Toronto.
Dr. Ken Sokoll PhD, Head of Development
Dr. Sokoll has managed several groups in Canada, the U.S. and Europe, including companies such as Aventis-Pasteur (now Sanofi) and United Biomedical Inc. with increasing responsibilities in the fields of pharmaceutical development and regulatory affairs. He has more than two decades of direct experience in the development of small molecule drugs and biologics specializing in advancing lead clinical candidates through the IND/CTA process and into Phase I and II clinical trials. Dr. Sokoll received his Ph.D. in Organic Chemistry from the University of Waterloo.